# 2025-22495: DEA Plays Chemical Whack-A-Mole With Designer Drug CUMYL-PEGACLONE

2025-22495, Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I, is a Federal Register proposed rule from Justice Department, Drug Enforcement Administration published 2025-12-11, effective Comments must be submitted electronically or postmarked on or before January 12, 2026. (See DATES section.) (as of 2026-06-11).

- Canonical: https://policyrisk.com/federal-register/2025-22495
- As of: 2026-06-11
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-22495
- Title: Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
- Type: Proposed Rule
- Agencies: Justice Department; Drug Enforcement Administration
- Citation: 90 FR 57534
- Published: 2025-12-11
- Effective: Comments must be submitted electronically or postmarked on or before January 12, 2026. (See DATES section.)
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-11

## In one line

DEA Plays Chemical Whack-A-Mole With Designer Drug CUMYL-PEGACLONE

## Summary

The Drug Enforcement Administration wants to make the temporary ban on CUMYL-PEGACLONE permanent by placing it in Schedule I, meaning it’s considered very risky and illegal to handle without special permission. This affects anyone who makes, sells, studies, or possesses this substance. Comments and hearing requests are open until January 12, 2026, so speak up before then!

## Abstract

The Drug Enforcement Administration proposes placing the substance CUMYL-PEGACLONE (SGT-151; 5-pentyl-2-(2-phenylpropan-2- yl)pyrido[4,3-b]indol-1-one), including its salts, isomers (including optical, positional, and geometric isomers), and salts of isomers, in schedule I of the Controlled Substances Act. CUMYL-PEGACLONE was temporarily scheduled in an order dated December 12, 2023. This action is being taken, in part, to enable the United States to meet its obligations under the 1971 Convention on Psychotropic Substances. If finalized, this action would make permanent the existing regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle CUMYL-PEGACLONE.

## Effects PRIA read

- CUMYL-PEGACLONE moved to Schedule I: cost, low. The Drug Enforcement Administration proposes to permanently place CUMYL-PEGACLONE (also called SGT-151) in Schedule I, making permanent the temporary controls first ordered on December 12, 2023. If finalized, anyone who manufactures, distributes, imports, exports, researches, or possesses this subs…
- Required registrations, security, and controls: cost, low. If finalized, anyone handling CUMYL-PEGACLONE must follow Schedule I requirements: register with DEA, meet Schedule I security rules, use specified labeling and packaging, comply with manufacturing quotas, keep initial and biennial inventories, maintain records and reports, use required order forms…
- Unauthorized handling may bring penalties: cost, medium. The proposal says any activity with CUMYL-PEGACLONE that is not authorized under the Controlled Substances Act would be unlawful and may subject the person to administrative, civil, and/or criminal sanctions under Schedule I rules.

## Related documents

- [2026-11526](https://policyrisk.com/federal-register/2026-11526): Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 201…, 2026-06-09
- [2026-10128](https://policyrisk.com/federal-register/2026-10128): Revision of Applications for Manufacturing and Procurement Quotas, 2026-05-20
- [2025-05007](https://policyrisk.com/federal-register/2025-05007): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-03-24
- [2025-02793](https://policyrisk.com/federal-register/2025-02793): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-02-19
- [2026-22843](https://policyrisk.com/federal-register/2026-22843): Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ep…, 2026-11-10
- [2026-22842](https://policyrisk.com/federal-register/2026-22842): Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sal…, 2026-11-10

## Sources
- [2025-22495 on federalregister.gov](https://www.federalregister.gov/documents/2025/12/11/2025-22495/schedules-of-controlled-substances-placement-of-cumyl-pegaclone-in-schedule-i)
- [2025-22495 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-12-11/pdf/2025-22495.pdf)

## Related
- [Previous: 2025-22490, Guidance on Response Programs for Unauthorized Access to Member Information and…](https://policyrisk.com/federal-register/2025-22490)
- [Next: 2025-22499, Establishment of Class E Airspace; Providence Seaside Hospital Heliport, Seasid…](https://policyrisk.com/federal-register/2025-22499)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-22495 (as of 2026-06-11).
